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Previous studies have primarily interpreted gene expression regulation by glucocorticoids
in the brain in terms of impact on neurons; however, less is known about the
corresponding impact of glucocorticoids on glia and specifically astrocytes in vivo.
Recent microarray experiments have identified glucocorticoid-sensitive mRNAs in primary
astrocyte cell culture, including a number of mRNAs that have reported astrocyte-enriched
expression patterns relative to other brain cell types. Here, we have tested whether
elevations of glucocorticoids regulate a subset of these mRNAs in vivo following
acute and chronic corticosterone exposure in adult mice. Acute corticosterone exposure
was achieved by a single injection of 10mg/kg corticosterone, and tissue samples
were harvested 2h post-injection. Chronic corticosterone exposure was achieved by
administering 10mg/mL corticosterone via drinking water for 2 weeks. Gene expression
was then assessed in two brain regions associated with glucocorticoid action (prefrontal
cortex and hippocampus) by qPCR and by in situ hybridization. The majority of measured
mRNAs regulated by glucocorticoids in astrocytes in vitro were similarly regulated by
acute and/or chronic glucocorticoid exposure in vivo. In addition, the expression levels
for mRNAs regulated in at least one corticosterone exposure condition (acute/chronic)
demonstrated moderate positive correlation between the two conditions by brain region.
In situ hybridization analyses suggest that select mRNAs are regulated by chronic
corticosterone exposure specifically in astroctyes based on (1) similar general expression
patterns between corticosterone-treated and vehicle-treated animals and (2) similar
expression patterns to the pan-astrocyte marker Aldh1l1. Our findings demonstrate
that glucocorticoids regulate astrocyte-enriched mRNAs in vivo and suggest that
glucocorticoids regulate gene expression in the brain in a cell type-dependent fashion.
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INTRODUCTION
At the level of the organism, stress occurs via environmental
or psychological stimuli (stressors) that disrupt homeostasis.
The classic stress response involves communication between
the brain and the rest of the body through the hypothalamic-
pituitary-adrenal (HPA) axis. In response to stress, the brain
integrates signals through the brainstem and the limbic system
(e.g., prefrontal cortex, hippocampus, and amygdala), which
in turn activates signaling cascades through the hypothalamus
and pituitary gland that result in the stimulation of the adrenal
glands and release of glucocorticoids into the circulatory system.
Glucocorticoids are the major output hormones of the HPA axis
and enable the organism to adapt to stressors by influencing
many physiological pathways (e.g., modulate attention and
appraisal, alter energy metabolism, regulate immune signaling,
modulate memory formation, etc.) (De Kloet et al., 2005; Lupien
et al., 2009). Glucocorticoids also act in negative feedback
mechanisms at multiple levels of the HPA axis (e.g., limbic
system, hypothalamus) to regulate stress response activation and
return the system to baseline following stress. Appropriate stress
response is thus critical for appropriate responsiveness to external
stimuli. Chronic disruption of appropriate stress signaling (e.g.,
altered HPA axis signaling, chronic stress) can have drastic impact
on well-being and has been linked to numerous disease states,
including Cushing’s disease [HPA hyperactivity (Newell-Price
et al., 2006)], Addison’s disease [HPA hypoactivity (Ten et al.,
2001)], and multiple psychiatric disorders, including depression
and bipolar disorder (McEwen, 2005). Given the importance of
the stress response to health and disease, there is great interest in
understanding the impact of glucocorticoids on the brain, both
in terms of acute exposure (e.g., stress mechanisms) and chronic
exposure (e.g., disease states).
At the cellular level, glucocorticoids are known to act as tran-
scriptional regulators through interaction with their associated
receptors (i.e., mineralocorticoid receptor, glucocorticoid recep-
tor) (Strachan and Read, 1999). These receptors have unique
neuroanatomical expression patterns but are both prominently
expressed in limbic structures (e.g., prefrontal cortex, hippocam-
pus) to facilitate HPA axis signaling. Glucocorticoids readily pass
through the cell membrane and bind their inactive receptors
that are complexed with chaperone proteins in the cytoplasm.
Ligand-bound receptors are activated and translocate to the
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nucleus [mechanisms reviewed in Vandevyver et al. (2012)].
Activated receptors can bind to DNA sequences known as glu-
cocorticoid response elements (GREs) and upregulate or down-
regulate target gene expression. Glucocorticoids are known to
regulate many mRNAs in the brain. While numerous studies have
reported in vitro findings of glucocorticoid regulation on a gene
by gene basis, fewer studies have looked at glucocorticoid reg-
ulation in the brain at the level of the transcriptome in vivo.
A limited number of gene expression profiling studies of gluco-
corticoid mRNA regulation using brain tissue have found that
numerous mRNAs are regulated by glucocorticoids in hippocam-
pal slices (Datson et al., 2001) and that the observed regulation
varies by the duration of glucocorticoid exposure (Morsink et al.,
2006).
The brain consists of many diverse cell types (e.g., neurons,
astrocytes, oligodendrocytes, microglia) that vary significantly in
function. Historically, investigations of the brain have focused on
neurons, but there is increasing evidence that glial cells play an
active role in numerous brain processes. Astrocytes participate
in many functions, including neurotransmission regulation, elec-
trical coupling and gap junctions, gliotransmission, metabolism
and the blood brain barrier, and astrogliosis and immune func-
tion [reviewed in Maragakis and Rothstein (2006)]. In addition
to the growing functional importance of glial cells, all of these
cell types are known to express glucocorticoid receptors and are
thus likely responsive to glucocorticoid signaling (McEwen et al.,
1968; Vielkind et al., 1990; Sierra et al., 2008). Previous studies
examining the impact of glucocorticoids upon brain tissues have
routinely interpreted the action of these steroids in terms of neu-
ronal physiology, but glucocorticoids are also known to impact
glial cells. For example, glucocorticoids can inhibit astrocyte pro-
liferation in vivo (Unemura et al., 2012). In terms of mRNA
regulation, glucocorticoids have been shown to regulate a limited
number of astrocyte mRNAs, including glutamine synthetase and
glial fibrillary acidic protein (GFAP) (Nichols et al., 1990; Laping
et al., 1994). Beyond these limited reports, the impact of glucocor-
ticoids on global gene expression in cell types other than neurons
in the brain is largely unknown.
There is also a clinical interest in understanding how gluco-
corticoids impact astrocytes due to their growing association with
major depression, a disorder strongly associated with altered HPA
axis signaling. Postmortem morphological studies have observed
changes in astrocytes associated with depression (e.g., decreased
astrocyte density and increased astrocyte size in prefrontal cortex)
(Rajkowska et al., 1999; Miguel-Hidalgo et al., 2000), and post-
mortem brain transcriptional profiling studies have also identi-
fied astrocyte-associated mRNAs as being altered in depression
(Barley et al., 2009; Bernard et al., 2010). However, how and even
if glucocorticoids influence astrocytes in pathological conditions
such as depression is currently speculative, and the extent of glu-
cocorticoid regulation occurring in astrocytes in vivo under basal
conditions is not well-understood. We recently characterized glu-
cocorticoid receptor-mediated regulation of mRNAs in cortical
and hippocampal astrocytes in vitro, defining glucocorticoid-
regulated mRNA targets that included both astrocyte-specific
mRNAs and mRNAs ubiquitously expressed among cell types
in the brain (Carter et al., 2012). However, the physiological
relevance of this glucocorticoid regulation observed in astrocyte
cell culture has not been investigated in the intact brain. Here we
have assessed whether a subset ofmRNAs regulated by glucocorti-
coids in astrocytes in vitro are responsive to glucocorticoids in vivo
following acute and chronic glucocorticoid exposure, including
mRNAs reported to be enriched in astrocytes (Cahoy et al., 2008).
MATERIALS ANDMETHODS
ANIMAL TREATMENTS AND BRAIN TISSUE COLLECTION
All animal procedures at the University of Michigan were
approved by UCUCA (University Committee on Use and Care
of Animals) and monitored by ULAM (Unit for Laboratory
Animal Medicine). Adult C57B/6 male mice (8 weeks of age)
were obtained from Charles River. For all experiments, mice
were group-housed (n = 3–5 per cage). Mice were housed for
1 week under basal conditions (14:10 light dark cycle) before
experiments. To collect tissue samples, mice were euthanized
using cervical dislocation and decapitation. For both the acute
and chronic glucocorticoid exposure protocols, upon euthanasia,
trunk blood was collected, and brains were removed and bisected
along the mid-sagittal plane. One brain hemisphere was frozen in
chilled isopentane (−35◦C) and stored at −80◦C for subsequent
tissue sectioning and in situ hybridization analyses. The remain-
ing brain hemisphere was further dissected on wet ice to collect
hippocampi and prefrontal cortex tissues for quantitative PCR
(qPCR) analyses. These tissue samples were frozen immediately
on dry ice and stored at −80◦C for subsequent RNA extraction.
ACUTE GLUCOCORTICOID MOUSE MODEL
Mice were injected (s.c.) with 10mg/kg corticosterone or vehicle
(1% ethanol solution) 1 h after lights on. Mice were returned to
their home cages for specified time durations prior to euthanasia
and sample collection. Corticosterone (Cort, Cat. #C2505) was
obtained from Sigma Aldrich.
CHRONIC GLUCOCORTICOID MOUSE MODEL
Chronic corticosterone exposure was produced based on pre-
viously published protocols (Gourley et al., 2008; Karatsoreos
et al., 2010; Lee et al., 2010). Mice were given access to drink-
ing water containing 10 mg/mL corticosterone or vehicle for 2
weeks (n = 5/group). Drinking solutions were replaced 3 times
over course of 2 weeks (every 4–5 days). On day 14, mice were
weighed on an analytical balance. Mice were then euthanized 1 h
after lights on, and brains were removed. Adrenal glands, spleen,
and thymus tissues were dissected on ice and weighed on an
analytical balance.
PLASMA CORTICOSTERONE ASSAY
Immediately following decapitation, trunk blood was collected
andmixed with 0.5M EDTA (pH 8.0, final concentration in blood
sample ∼10μM) and stored immediately on wet ice. Blood sam-
ples were subsequently spun in a table-top centrifuge (3500 × g
for 10min at 4◦C). Blood plasma was transferred to a fresh 1.5mL
tube and stored at −80◦C. Plasma corticosterone concentrations
were measured using a corticosterone double antibody radioim-
munoassay kit (MP Biomedicals, Cat. #07120102). Individual
samples were measured in triplicate, including standard curve
controls; the average value was used for subsequent calculations.
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RNA ISOLATION
Total RNA samples were isolated from tissues using Trizol reagent
per manufacturer’s protocol (Invitrogen), and RNA concen-
trations were obtained using a Nanodrop spectrophotometer
(Thermo Scientific).
QUANTITATIVE PCR (qPCR) ANALYSIS
RNA samples (500 ng–1μg) were converted to cDNA using
Superscript II via random hexamer priming (Invitrogen).
Approximately Fifty percentage of each cDNA reaction was used
for Applied Biosystems (ABI) Taqman mRNA qPCR assays in
custom Low-Density Array (TLDA) format (ABI #4346799) with
Taqman reagents (ABI #4440048). The Taqman arrays were pro-
cessed on an Applied Biosystems Viia7 instrument according to
manufacturer protocols. mRNAs were selected for measurement
based on combinations of the following of factors as defined
previously (Carter et al., 2012); (1) glucocorticoid sensitivity vs.
insensitivity in primary astrocyte cultures, (2) magnitude of glu-
cocorticoid regulation, (3) previous reporting of glucocorticoid
sensitivity vs. novel glucocorticoid regulation, and (4) previous
association with astrocyte function and/or astrocyte-enrichment
(Cahoy et al., 2008). Previously reported glucocorticoid regu-
lation vs. novel glucocorticoid regulation was determined by
literature analysis of each individual gene (i.e., using PubMed
and Google Scholar search tools, terms used: gene symbol and/or
probe ID + “glucocorticoids, corticosteroids, corticosterone,
dexamethasone, prednisone”). mRNA expression was measured
in technical triplicate per sample. Taqman mRNA assays were
selected based on manufacturer recommendations; all but one
assay spanned exon-exon junctions (Glul). Specific Taqman
mRNA assays used in this analysis are: Actb (Mm01205647_g1),
Adora2b (Mm00839292_m1), Aldh1l1 (Mm00550947_m1),
Atp6v1b2 (Mm00431987_m1), Ch25h (Mm00515486_
s1), Egr2 (Mm00456650_m1), Fgfr1 (Mm00438930_m1),
Fgfr3 (Mm00433294_m1), Fkbp5 (Mm00487401_m1),
Folh1 (Mm00489655_m1), Foxo1 (Mm00490672_m1),
Gap43 (Mm00500404_m1), Gfap (Mm01253033_m1), Gja1
(Mm00439105_m1), Gjb6 (Mm01317508_m1), Glul (Mm
00725701_s1), Hdac7 (Mm00469520_m1), Klf9 (Mm00495172_
m1), Mapk4 (Mm00554001_m1), Mertk (Mm00434920_
m1), Pdk4 (Mm01166879_m1), Per1 (Mm00501813_m1),
Phlda1 (Mm00456345_g1), Prodh (Mm00448401_m1), Sgk1
(Mm00441380_m1), Slc1a2 (Mm00441457_m1), Slc1a3
(Mm00600697_m1), Sult1a1 (Mm01132072_m1), Syn2
(Mm00449780_m1), Txnip (Mm00452393_m1), Wnt7a
(Mm00437354_m1). Gene symbols, definitions, and reported
astrocyte fold-enrichment (Cahoy et al., 2008) for measured
mRNAs are listed in Table 1.
In situ HYBRIDIZATION (ISH)
Brain hemisections were cut on a cryostat (10μm thick),
mounted on Superfrost microscope slides (2 sections per slide),
and stored at −80◦C prior to ISH experiments. To create
ISH probes, specific mRNA domains that displayed low lev-
els of nucleotide homology were amplified by PCR (Native Taq
DNA polymerase, Invitrogen) using primers designed with NCBI
Primer Blast software (Table 2). PCR amplicons were cloned
Table 1 | mRNAs assessed for glucocorticoid regulation in the brain
in vivo.
Symbol Gene (protein) Astrocyte
fold-enrichment*
Adora2b Adenosine A2b receptor 17.4
Aldh1l1 Aldehyde dehydrogenase 1 family,
member L1
54.0
Atp6v1b2 V-ATPase B2 subunit –
Ch25h Cholesterol 25-hydroxylase –
Egr2 Early growth response protein 2 –
Fgfr1 Fibroblast growth factor receptor 1 8.8
Fgfr3 Fibroblast growth factor receptor 3 27.2
Fkbp5 FK506 binding protein 5 –
Folh1 Folate hydrolase 1 11.4
Foxo1 Forkhead box protein O1 3.8
Gap43 Growth associated protein 43 –
Gfap Glial fibrillary acidic protein 84.9
Gja1 Gap junction protein, alpha 1
(connexin-43)
20.9
Gjb6 Gap junction protein, beta 6
(connexin-30)
32.7
Glul Glutamine synthetase 8.5
Hdac7 Histone deacetylase 7 –
Klf9 Kruppel-like factor 9 3.1
Mapk4 Mitogen-activated protein kinase 4 5.6
Mertk C-mer proto-oncogene tyrosine
kinase
33.0
Pdk4 Pyruvate dehydrogenase kinase,
isozyme 4
20.8
Per1 Period circadian clock 1 1.9
Phlda1 Pleckstrin homology-like domain
family A member 1
–




Slc1a2 Solute carrier family 1, member 2
(EAAT2/GLT-1)
46.7
Slc1a3 Solute carrier family 1, member 3
(EAAT1/GLAST)
43.0
Sult1a1 Sulfotransferase 1A1 12.8
Syn2 Synapsin II –
Txnip Thioredoxin-interacting protein 5.3
Wnt7a Wingless-related MMTV integration
site 7A
7.6
*mRNA expression in astrocytes compared to neurons and oligodendrocytes
(Cahoy et al., 2008).
into pCR-II-TOPO Vector; plasmids were transformed using
TOP10 cells (Invitrogen). Plasmid DNA was isolated using a
QIAprep Spin Miniprep Kit (Qiagen). The identity of all plasmid
clones was verified by Sanger Sequencing (DNA sequencing core,
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University of Michigan). Plasmids were linearized using appro-
priate restriction enzymes (NEB). Linearized plasmids were used
to create 35S-RNA probes using T7 or SP6 RNA polymerases
(varied by plasmid). Briefly, linearized plasmid (100–500 ng) was
combined with 1μl each of ATP, GTP, and CTP (10mM), 1μl
RNAse inhibitor, 1.66μl DTT (100μM), 4μl 5 × transcription
buffer (Promega) and 7.8μl of 35S-UTP (12.5 μCi/ul, Perkin
Elmer). Probes were purified using BioRad P-6 columns; the efflu-
ent was measured with a scintillation counter and then diluted
with hybridization solution (∼2 × 106 cpms of probe in 40μl
hybridization buffer per slide). All remaining tissue process-
ing steps were performed according to published lab protocols
(Carter et al., 2010). Probe hybridization specificity was defined in
control experiments by sense probes which failed to yield autora-
diographic signals above background. Sense probes demonstrate
significantly lower signal compared to antisense probes for all
mRNAs assessed (Figure 1).
Table 2 | Primers for in situ hybridization probes.







*Primers listed 5 ′ ≥ 3 ′ .
FIGURE 1 | Specificity of mRNA in situ hybridization probes. Sense
(Left) and antisense (Right) comparisons of ISH probe signal under
matched exposure times per probe.
DENSITOMETRY ANALYSIS
Anatomical boundaries of the prefrontal cortex and hippocam-
pus where defined based upon reference to the mouse brain
atlas of Paxinos and Franklin (2001). Autoradiograms from ISH
were scanned with a ScanMaker 1000XL Pro Flatbed Scanner
(Microtek, Carson, CA) using SilverFast Ai Imaging Software
(LaserSoft Imaging, Sarasota, FL). The scanned images were ana-
lyzed based on optical density (OD) measurements using ImageJ
software (Version 1.45S, NIH). For each probe, a normalized
OD value for each section image was determined by subtracting
a background value from the OD value (Background = back-
ground mean + 3.5 ∗ standard deviation of background mean).
Background measurements were taken from a non-tissue area
of each film. Four section images were measured for each brain
region per animal; an average normalized value of the 4 sections
per probe was used for downstream analyses.
STATISTICAL ANALYSIS
For qPCR experiments, differential expression analysis was per-
formed using the delta-delta-Ct method [(Livak and Schmittgen,
2001), β-actin as control reference] using Statminer software
(Integromics). An average of Ct-values from technical replicates
was taken as the Ct-value for each gene measurement; individual
Ct-values identified as outliers via the Grubbs’ outlier test were
excluded from downstream analyses. For comparisons between
groups in terms of qPCR analysis of mRNA differential expres-
sion, measurements were compared using a moderated t-test;
statistical significance was defined as p < 0.05. The relationship
between corticosterone levels over time due to corticosterone
injection was analyzed using a Two-Way ANOVA with multi-
ple replicates; comparison of groups at individual time points
was performed post-hoc using Fisher’s least-significant difference
(LSD) test. For individual comparisons between groups in terms
of organ weight, body weight, corticosterone levels, and ISH
analysis, measurements were compared using a two-tailed stu-
dent’s t-test; statistical significance was defined as p < 0.05. The
standard error of the mean (SEM) was used for error bars on
graphs.
RESULTS
SINGLE CORTICOSTERONE INJECTION RESULTS IN TRANSIENT RISE
OF CORTICOSTERONE PLASMA LEVELS
In order to determine the plasma concentrations of corticos-
terone in vivo following a single bolus injection of corticosterone,
3 sets of mice were injected with 10mg/kg corticosterone or
vehicle solution, and blood samples were then collected at 1,
2, and 4 h post-injection (n = 3 animals/group/time point, 18
animals total; Figure 2A). Two-Way ANOVA revealed a signifi-
cant effect of treatment [F(1, 12) = 9.54, p = 0.009], time point
[F(2, 12) = 7.08, p = 0.009] and a significant interaction between
treatment and time point [F(2, 12) = 5.51, p = 0.02]. Post-hoc
comparisons revealed a trend for a significant effect of treatment
on corticosterone levels at 1 h (Fisher’s LSD p = 0.06). Overall,
corticosterone-treated animals tended to exhibit higher corticos-
terone levels at each time point compared with vehicle-treated
animals, and the difference between treatment groups was depen-
dent on the length of exposure. Specifically, a 10mg/kg dose of
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corticosterone increased plasma corticosterone concentration to
a supraphysiological level by 1 h. The plasma corticosterone level
remained significantly elevated at 2 h at levels similar in magni-
tude to acute stress (Ma et al., 1997; McClennen et al., 1998) and
then returned to near baseline by 4 h. Given the robust increase
in plasma corticosterone levels during the initial hours post-
injection, we chose to analyze gene expression 2 h post-injection
in subsequent experiments, a time point temporally consistent
with direct glucocorticoid-based transcriptional mechanisms. A
replicate experiment yielded a corticosterone elevation of simi-
lar magnitude, and samples from this second experiment were
used for subsequent qPCR experiments (n = 8 animals/group,
Figure 2B).
SINGLE INJECTION OF CORTICOSTERONE RESULTS IN mRNA
REGULATION IN BRAIN in vivo OF mRNAs PREVIOUSLY REPORTED TO
BE REGULATED BY GLUCOCORTICOIDS IN ASTROCYTES in vitro
mRNA levels for select genes in RNA samples derived from
two brain regions (prefrontal cortex and hippocampus) of mice
FIGURE 2 | Single injection of 10mg/kg corticosterone results in
transient rise in plasma corticosterone levels in mice. (A) Time course
of plasma corticosterone levels following injection (n = 3/treatment/time
point). (B) Plasma corticosterone levels in mice (2 h post-injection exposure)
used in qPCR experiments (n = 8/group). Error bars = SEM. ∗p < 0.05.
injected with corticosterone or vehicle solution were measured by
qPCR using Taqman Low Density Arrays (TLDAs). 18 mRNAs
were measured based on robust glucocorticoid-sensitivity in
astrocytes in vitro (Carter et al., 2012). Twelve of these 18
mRNAs were statistically regulated by acute corticosterone expo-
sure in vivo in at least one of the brain regions tested (Figure 3).
Among all mRNAs measured, 6 mRNAs were differentially
expressed in both cortex and hippocampus following acute corti-
costerone treatment (upregulated; Fkbp5, Gjb6, Klf9, Pdk4, Sgk1,
Sult1a1). 2 mRNAs were regulated in cortex but not in hip-
pocampus (upregulated: Txnip; downregulated: Phlda1), and 6
mRNAs were regulated in hippocampus but not cortex (upreg-
ulated: Adora2b, Egr2; downregulated: Hdac7, Prodh, Slc1a2,
Wnt7a). 15 mRNAs that have been reported to be regulated
by glucocorticoids in vitro [listed in Carter et al. (2012)] were
not statistically regulated in either brain region by acute cor-
ticosterone exposure in vivo (previously reported upregulation:
Ch25h, Folh1, Foxo1, Gap43, Glul, Mapk4, Mertk, Per1, Syn2;
previously reported downregulation: Atp6v1b2, Gfap). 3 mRNAs
were regulated by acute corticosterone treatment in vivo that were
not regulated or regulated in the opposite direction by gluco-
corticoids in astrocytes in vitro (downregulated: Hdac7, Slc1a2;
downregulated instead of upregulated: Egr2). The magnitude
of regulation induced by acute corticosterone exposure in this
condition ranged from+3.15-fold regulation (Sgk1 in hippocam-
pus) to +0.65/−1.55-fold regulation (Egr2 in hippocampus).
Complete numerical values of mRNA regulation by acute corti-
costerone exposure in vivo and corresponding statistical p-values
for all mRNAs measured are listed in Table 3.
MICE GIVEN EXTENDED ACCESS TO DRINKING WATER CONTAINING
CORTICOSTERONE DEMONSTRATE HORMONAL AND ORGAN
CHANGES CONSISTENT WITH ACUTE AND CHRONIC
GLUCOCORTICOID ELEVATION
Mice given access to drinking water containing corticosterone
for 14 days displayed statistically elevated corticosterone plasma
levels relative to mice given access to vehicle drinking water
FIGURE 3 | Acute corticosterone exposure regulates select
mRNAs in hippocampus and prefrontal cortex. Gene expression
fold-change ratios for mRNAs regulated by glucocorticoids in
astrocytes in vitro (Carter et al., 2012) in prefrontal cortex and
hippocampus following injection of 10mg/kg corticosterone vs.
saline control in vivo (2 h post-injection exposure, n 8 per
group). Dashed line indicates no change compared to vehicle.
Error bars = SEM. ∗p < 0.05.
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Table 3 | qPCR data for all mRNAs measured for mRNA regulation by acute and chronic corticosterone exposure in the brain in vivo.
mRNA Acute Ctx Acute Ctx Acute Hip Acute Hip Chronic Ctx Chronic Ctx Chronic Hip Chronic Hip
FC p-value FC p-value FC p-value FC p-value
Adora2b 1.143 1.18E-01 1.156 4.43E-02 0.646 2.17E-02 0.619 3.51E-03
Aldh1l1 1.097 7.06E-02 1.039 6.32E-01 1.155 4.05E-01 1.060 5.80E-01
Atp6v1b2 0.985 8.25E-01 0.980 7.50E-01 1.022 8.97E-01 0.984 8.74E-01
Ch25h 0.681 1.47E-01 0.762 2.95E-01 0.595 7.55E-03 1.490 5.80E-01
Egr2 0.770 8.66E-02 0.645 3.06E-03 0.430 1.20E-02 0.692 9.37E-02
Fgfr1 1.155 1.21E-01 1.013 8.53E-01 0.395 1.13E-03 0.862 1.57E-01
Fgfr3 0.931 7.18E-01 1.019 8.53E-01 2.196 2.64E-04 0.669 9.37E-02
Fkbp5 2.716 1.86E-10 1.812 2.46E-10 3.540 1.03E-04 1.861 2.37E-04
Folh1 1.011 8.72E-01 0.950 4.16E-01 0.881 5.07E-01 1.311 3.24E-02
Foxo1 1.145 2.94E-01 0.913 3.05E-01 0.610 2.73E-03 1.102 4.20E-01
Gap43 1.120 7.93E-02 1.071 4.93E-01 0.955 7.74E-01 0.655 7.68E-04
Gfap 0.982 8.72E-01 0.922 3.05E-01 0.360 1.13E-03 0.633 6.17E-04
Gja1 1.077 2.94E-01 1.011 8.66E-01 0.669 2.15E-02 0.847 2.34E-01
Gjb6 1.254 1.90E-04 1.324 3.06E-03 1.269 1.69E-01 1.543 6.82E-04
Glul 1.179 5.47E-02 1.143 1.09E-01 1.585 1.67E-02 0.978 8.51E-01
Hdac7 0.886 1.21E-01 0.861 4.69E-02 0.825 2.29E-01 0.673 3.51E-03
Klf9 1.315 3.84E-04 1.186 1.17E-02 1.051 7.94E-01 1.178 1.23E-01
Mapk4 1.077 3.62E-01 0.929 3.36E-01 0.968 8.92E-01 1.158 3.81E-01
Mertk 1.107 3.24E-01 1.138 1.09E-01 1.279 2.25E-01 1.656 1.57E-03
Pdk4 1.596 2.01E-08 1.871 7.92E-09 1.087 5.89E-01 1.153 1.03E-01
Per1 1.161 1.47E-01 1.087 3.36E-01 0.860 4.05E-01 0.955 7.41E-01
Phlda1 0.807 2.09E-02 0.823 5.12E-02 0.859 4.01E-01 0.841 1.57E-01
Prodh 1.140 1.74E-01 1.180 4.86E-02 1.862 1.73E-03 1.557 3.96E-03
Sgk1 2.708 1.86E-10 3.150 9.20E-12 1.511 6.86E-03 1.946 1.23E-04
Slc1a2 0.997 9.60E-01 0.876 4.43E-02 0.727 4.97E-02 0.848 2.34E-01
Slc1a3 1.074 4.03E-01 0.923 3.05E-01 0.508 6.86E-03 0.856 1.49E-01
Sult1a1 2.130 2.01E-08 2.012 5.46E-10 3.774 2.65E-06 4.317 3.63E-08
Syn2 0.958 7.18E-01 1.046 5.07E-01 1.014 9.20E-01 0.751 3.73E-03
Txnip 1.464 2.84E-03 1.235 1.70E-01 0.916 7.04E-01 1.199 1.49E-01
Wnt7a 0.857 3.76E-01 0.754 4.09E-03 0.308 6.86E-03 0.589 6.17E-04
Ctx, cortex; Hip, hippocampus; yellow, p < 0.05.
(Figure 4A). Chronic corticosterone-treated mice also had sig-
nificantly reduced thymus, adrenal, and spleen organ weights
compared to vehicle-treated mice (Figure 4B), data consistent
with chronic glucocorticoid exposure. There was no difference in
the total body weight between treatment groups (Figure 4C).
CHRONIC CORTICOSTERONE EXPOSURE RESULTS IN mRNA
REGULATION IN BRAIN in vivo OF mRNAs PREVIOUSLY REPORTED TO
BE REGULATED BY GLUCOCORTICOIDS IN ASTROCYTES in vitro
mRNA levels for select genes in RNA samples derived from
two brain regions (prefrontal cortex and hippocampus) of mice
treated with chronic corticosterone solution or vehicle solution
were measured by qPCR using TLDAs. Of the 18 mRNAs mea-
sured that were regulated by glucocorticoids in astrocytes in vitro
(Carter et al., 2012), 12 of these mRNAs were statistically regu-
lated by chronic corticosterone exposure in vivo in at least one of
the brain regions tested (Figure 5). Among all mRNA measured,
7 mRNAs were regulated by chronic corticosterone exposure in
both cortex and hippocampus (upregulated: Adora2b, Fkbp5,
Prodh, Sgk1, Sult1a1; downregulated: Gfap, Wnt7a). 9 mRNAs
were regulated by chronic corticosterone exposure in cortex but
not in hippocampus (upregulated: Ch25h, Egr2, Fgfr3, Foxo1,
Glul; downregulated: Ch25h, Fgfr3, Gja1, Slc1a2, Slc1a3); 6
mRNAs were regulated by chronic corticosterone exposure in
hippocampus but not cortex (upregulated: Folh1, Gap43, Gjb6,
Mertk, Syn2; downregulated: Hdac7). 7 mRNAs that have been
reported to be regulated in vitro were not regulated in either
region by chronic corticosterone exposure in vivo [previously
reported upregulation: Klf9, Mapk4, Per1, Pdk4, Txnip; previ-
ously reported downregulation: Atp6v1b2, Phlda1; referenced in
(Carter et al., 2012)]. 15 mRNAs were regulated in at least one
brain region in a manner consistent with previously reported
glucocorticoid regulation in vitro [listed in Carter et al. (2012)]
(upregulated: Adora2b, Fkbp5, Folh1, Gap43, Gjb6, Glul, Mertk,
Prodh, Sgk1, Sult1a1, Syn2; downregulated: Ch25h, Gfap, Gja1,
Wnt7a) (Figure 5A). In addition, 12 mRNAs were regulated by
chronic corticosterone treatment in vivo that were not regulated
or regulated in the opposite direction by glucocorticoids in astro-
cytes in vitro (upregulated: Fgfr3; downregulated: Fgfr1, Foxo1,
Gap43, Gfap, Gja1, Hdac7, Slc1a2, Slc1a3, Syn2; downregulated
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FIGURE 4 | Chronic corticosterone administration via drinking
water results in acute and chronic corticosterone elevations. (A)
Plasma corticosterone levels after 2 weeks access to drinking water
containing 10mg/mL corticosterone vs. vehicle. (B) Weights of
corticosterone-sensitive organs after chronic corticosterone
administration. (C) Body weight of mice after chronic corticosterone
administration. N = 5 per group. Error bars = SEM. ∗∗∗p < 0.0001.
ns = not significant.
FIGURE 5 | Chronic corticosterone exposure regulates select mRNAs
in hippocampus and prefrontal cortex. (A) Gene expression
fold-change ratios for mRNAs regulated by glucocorticoids in astrocytes
in vitro (Carter et al., 2012) in prefrontal cortex and hippocampus
following chronic corticosterone exposure for 2 weeks vs. vehicle
control (n = 8 per group). (B) mRNA fold-changes of mRNAs regulated
by chronic corticosterone exposure in vivo that were not regulated by
glucocorticoids in astrocytes in vitro or acute corticosterone exposure
in vivo. Dashed line indicates no change compared to vehicle. Error
bars = SEM. ∗p < 0.05.
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instead of upregulated: Egr2, Adora2b) (Figure 5B). The magni-
tude of regulation induced by chronic corticosterone exposure
in this condition ranged from +4.38-fold regulation (Sult1a1
in hippocampus) to +0.31/−3.24-fold regulation (Wnt7a in
frontal cortex). Complete numerical values of mRNA regulation
by chronic corticosterone exposure in vivo and corresponding
statistical p-values are for all mRNAs measured are listed in
Table 3.
SELECT mRNAs REGULATED BY CHRONIC CORTICOSTERONE
EXPOSURE in vivo HAVE NEUROANATOMICAL EXPRESSION PATTERNS
CONSISTENT WITH ASTROCYTE MARKER ALDH1L1
Regulation of select mRNAs by chronic corticosterone expo-
sure was further assessed in the prefrontal cortex and hip-
pocampus by semi-quantitative radioactive in situ hybridization
(Figure 6). These mRNAs were selected based on previously
reported glucocorticoid sensitivity (Fkbp5, Gfap, Glul), their
regulation by chronic corticosterone exposure in cortex and/or
hippocampus based on qPCR measurements (Fkbp5, Gfap, Gja1,
Gjb6, Glul), and/or an established association with astrocyte
localization and function (Aldh1l1, Gfap, Gja1, Gjb6, Glul). Of
the 6 mRNAs examined via in situ hybridization, 3 mRNAs were
statistically regulated in at least one brain region in the same
direction as the qPCR data (upregulated: Fkbp5, Gfap, Gjb6). 2
mRNAs demonstrated non-significant trends in the same direc-
tion as the qPCR data (upregulated: Glul; downregulated: Gja1),
and 1 mRNA demonstrated differential expression in at least
one brain region that was not observed by qPCR (upregulated:
Aldh1l1). In terms of hippocampal expression patterns between
chronic corticosterone treatment and vehicle treatment, these
mRNAs showed generally consistent expression patterns between
treatment groups (Figure 6A). Fkbp5 appeared predominantly
FIGURE 6 | ISH measures of select mRNAs confirm chronic
corticosterone regulation and reveal mRNA expression patterns
consistent with pan-astrocyte marker Aldh1l1 (A). Representative
images of in situ hybridization data for select mRNAs in hippocampus.
(B,C) in situ hybridization densitometry measures of differential mRNA
expression in whole hippocampus (B) and prefrontal cortex (C).
n = 5/group. Dashed line = no change compared to vehicle. ∗p < 0.05.
#sub-threshold ISH signal.
Frontiers in Neuroscience | Neuroendocrine Science August 2013 | Volume 7 | Article 139 | 8
Carter et al. Glucocorticoid-mediated astrocyte-enriched mRNA regulation in vivo
expressed in pyramidal cell hippocampal subfields, while expres-
sion of Gfap, Gja1, Gjb6, and Glul was noticeably lacking in
the pyramidal cell regions but displayed diffuse levels of expres-
sion in molecular cell regions. This latter anatomical distribution
was highly similar to the expression pattern of the pan-astrocytic
marker Aldh1l1 (Figure 6A).
ACUTE CORTICOSTERONE EXPOSURE in vivo AND CHRONIC
CORTICOSTERONE EXPOSURE in vivo (1) REGULATE DISTINCT SETS OF
mRNAs AMONG mRNAs PREVIOUSLY REPORTED TO BE REGULATED BY
GLUCOCORTICOIDS IN ASTROCYTES in vitro AND (2) DEMONSTRATE
POSITIVE CORRELATION AMONG THE EXPRESSION LEVELS OF
REGULATED mRNAs BETWEEN CONDITIONS
Comparison of select mRNAs measured by qPCR that were reg-
ulated by glucocorticoids in astrocytes in vitro [18 regulated
mRNAs, (Carter et al., 2012)], acute corticosterone exposure
in vivo (14 regulated mRNAs), or chronic corticosterone expo-
sure in vivo (22 regulated mRNAs) revealed significant overlap
yet also distinct patterns of mRNA regulation between conditions
(in vitro + acute overlap: 10 mRNAs, in vitro + chronic over-
lap: 12 mRNAs, acute + chronic overlap: 10 mRNAs, Figure 7).
For mRNAs regulated in multiple conditions, the directional-
ity of glucocorticoid regulation was generally consistent across
conditions (Figure 7A). 8 mRNAs were regulated in all three
conditions, and all mRNAs regulated by acute corticosterone
exposure in vivo were also regulated in one of the other condi-
tions (Figure 7B). AmongmRNAs regulated by glucocorticoids in
at least one in vivo condition, there was a moderate, positive cor-
relation among the measured mRNAs between mRNA expression
changes between the two conditions (cortex correlation coeffi-
cient R = 0.641, hippocampus correlation coefficient R = 0.720)
(Figure 7C).
FIGURE 7 | Summary of results for measured mRNAs regarding
glucocorticoid regulation by acute corticosterone exposure and
chronic corticosterone exposure in vivo. (A) Heatmap summarizing
directionality of glucocorticoid regulation of mRNAs across conditions.
Key summarizes table terminology. (B) Proportional Venn diagram
comparing measured mRNAs regulated by glucocorticoid treatment
among 3 experimental conditions (astrocytes in vitro, acute exposure
in vivo, chronic exposure in vivo). (C) Plot of mRNA regulation by
acute corticosterone exposure vs. mRNA regulation by chronic
corticosterone exposure for all mRNAs regulated in at least one
in vivo condition (log2 scale). Regulated = p < 0.05. ∗ in vitro data
from Carter et al. (2012).
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DISCUSSION
Glucocorticoids are important mediators of the classic stress
response. Previous reports have characterized extensive
glucocorticoid-mediated mRNA regulation in CNS tissue
using in vitro systems and hippocampal slice models, demon-
strating that stress hormones indeed have a broad impact on
mRNA expression in the brain. Although many cell types in
the brain express receptors for glucocorticoids [e.g., neurons
(McEwen et al., 1968), astrocytes and oligodendrocytes (Vielkind
et al., 1990), microglia (Sierra et al., 2008)] and are thus presum-
ably responsive to glucocorticoids, most studies of glucocorticoid
signaling in the brain have interpreted resulting data in terms of
glucocorticoid regulation in neurons. Relatively little is known
about the impact of glucocorticoids on other brain cell types
(e.g., glia). We and others have recently investigated glucocor-
ticoid regulation in astrocytes in vitro using primary cortical
astrocyte cultures derived from newborn mice and reported
extensive time-dependent gene expression changes (Carter et al.,
2012; Slezak et al., 2013), including glucocorticoid regulation
of astrocyte-enriched mRNAs (Cahoy et al., 2008). While these
in vitro data are intriguing, physiological significance of these
results would hinge upon in vivo evidence of similar glucocor-
ticoid regulation of astrocyte-enriched mRNA expression. Here
we have examined the effect of exposing the brain to acute and
chronic glucocorticoid treatment in vivo on the expression of
select mRNAs that are regulated by glucocorticoids in astrocytes
in vitro.
We first determined if a subset of mRNAs robustly regulated
by short-term glucocorticoid treatment in astrocytes in vitro [i.e.,
18 mRNAs identified in Carter et al. (2012)] were also regu-
lated by acute glucocorticoid exposure in the brain in vivo. We
measured mRNA expression in prefrontal cortex and hippocam-
pus, two regions of well-characterized glucocorticoid action in
the brain. A majority of the measured mRNAs regulated by glu-
cocorticoids in astrocytes in vitro were also regulated by acute
corticosterone exposure in at least one brain region in vivo (12/18
regulated, Figure 3). Almost all of the observedmRNA regulation
in vivo was directionally consistent with the regulation in astro-
cytes in vitro (upregulated: Fkbp5, Gjb6, Prodh, Sgk1, Sult1a1,
Adora2b, Klf9, Pdk4, Txnip; downregulated: Wnt7a, Phlda1). A
portion of the regulated mRNAs are known to be both enriched
in astrocytes and involved in specific processes, such as cellu-
lar metabolism (Pdk4, Prodh, Sult1a1), intercellular signaling
(Adora2b, Gjb6, Slc1a2), and transcriptional regulation (Klf9,
Txnip). While these qPCR data do not identify the cell types in
which these glucocorticoid-mediated mRNA changes take place,
these data confirm that these mRNAs are glucocorticoid-sensitive
in vivo. An intriguing subsequent question will be to determine
if other physiological challenges known to acutely increase glu-
cocorticoids (e.g., stress) similarly regulate these same mRNAs.
Additionally, a portion of mRNAs regulated by glucocorticoids
in astrocytes in vitro were not regulated by acute corticosterone
treatment in the brain in vivo (Ch25h, Folh1, Glul, Mapk4,
Mertk). This result may indicate these particular mRNAs are not
regulated by elevated glucocorticoids in vivo or that the cellular
environment of the intact brain is sufficiently different than in
astrocytes in vitro and glucocorticoid regulation of these mRNAs
may be delayed and/or less robust in vivo. If these mRNAs are
indeed regulated in the brain by glucocorticoids, another pos-
sible explanation for no observed mRNA expression changes is
differential regulation by cell types; for example, glucocorticoids
has been shown to increase NGF mRNA expression in neu-
rons but decrease NGF expression in astrocytes (Lindholm et al.,
1992), a scenario that may result in no net change in tissue-
level mRNA expression. Alternatively, this acute corticosterone
exposure condition may not be sufficient to elicit regulation of
these mRNAs based on condition-dependent features (e.g., corti-
costerone dosage, relatively short duration of exposure). Overall,
given the previous reporting of the astrocyte-enrichment of many
mRNAs measured (Cahoy et al., 2008), the observed regulation
of many of these mRNAs suggests that astrocytes are acutely
responsive to glucocorticoids in vivo.
In general, the absolute magnitude of the glucocorticoid-
mediated changes observed in vivo was lower than mRNA expres-
sion differences observed following similar steroid treatment
durations in astrocytes in vitro. One potential explanation for
this difference may be due to the active clearance of glucocor-
ticoids from the brain compared to cell culture. In cell culture,
the glucocorticoid concentration remains high and relatively con-
stant, whereas there is a more temporally limited elevation of
corticosterone in the intact brain, likely resulting in less robust
regulation. Consistent with this possibility, active clearance of
plasma corticosterone was directly observed in the acute exposure
condition, returning corticosterone concentrations to baseline
within 4 h (Figure 2A). In general, the cellular environment in the
brain constantly strives to maintain homeostasis; in a situation
of elevated glucocorticoid levels, the brain would engage systems
to limit responsiveness to continued steroid exposure by acti-
vating opposing regulatory mechanisms to control the response
to changes induced by glucocorticoid signaling. There are also
less intercellular interactions in the isolated astrocyte cell culture
that may counteract or limit cell-type dependent glucocorti-
coid responses in vivo. Another possible mechanism influencing
the observed glucocorticoid regulation is steroid metabolism.
Neurons and glia contain enzymes that modify glucocorticoid
structure (e.g., 5-alpha-reductase) (Melcangi et al., 1993). The
models used in these experiments cannot distinguish between
regulation by corticosterone and associated metabolites in these
experiments; whether directly or indirectly, we can conclude that
these mRNAs are responsive to corticosterone treatment, but
changes in steroid metabolism may impact the magnitude of reg-
ulation [e.g., corticosterone metabolites have different affinities
for glucocorticoid receptor (McInnes et al., 2004)]. The role of
glucocorticoid metabolites in the regulation of these mRNAs in
the brain in vivo remains unresolved, which may be as or more
important as regulation by the natural ligand corticosterone.
Future studies that specifically utilize glucocorticoid metabolites
and/or include the use of glucocorticoid receptor antagonists
(e.g., RU—486) would aid in addressing this important issue.
Additionally, the previous in vitro astrocyte experiments were
focused on glucocorticoid receptor-mediated mRNA regulation;
given the presence of mineralocorticoid receptor in astrocytes and
the limbic system, differential receptor binding may also influ-
ence the observed mRNA regulation. Taken together, although
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the magnitude of mRNA regulation was reduced in vivo relative
to astrocytes in vitro, these data indicate that these mRNAs can
indeed be regulated in the brain by acute glucocorticoid exposure
in vivo.
Although these data involving acute glucocorticoid regulation
are relevant for understanding physiological glucocorticoid sig-
naling (e.g., stress response), clinical conditions involving alter-
ations in glucocorticoid signaling are often chronic in nature.
Given that our acute condition resulted in a temporary increase in
glucocorticoid levels, we wanted to further investigate regulation
of these mRNAs in response to chronically elevated glucocorti-
coid levels in the brain in vivo. We assessed the impact of chronic
glucocorticoid exposure onmice using an established protocol for
administering corticosterone via drinking water (Gourley et al.,
2008; Karatsoreos et al., 2010) (Figure 4). Consistent with prior
studies, 2 weeks of corticosterone treatment of mice lead to ele-
vated plasma levels of corticosterone, indicating that all mice
exposed to the corticosterone solution had consumed water con-
taining corticosterone at least in the short term. Physiological
indices of chronic corticosterone treatment were observed in the
form of hypotrophy of several glucocorticoid-sensitive tissues
(i.e., adrenal glands, thymus, and spleen). These indices were
observed without changes in body weight, suggesting limited sec-
ondary metabolic impact of this protocol. Together, these data
demonstrate that mice under this protocol show signs of acute
and chronic corticosterone exposure.
With evidence of chronic corticosterone exposure, we then
assessed glucocorticoid-mediated mRNA regulation in the brain.
Among the mRNAs measured, the majority of the mRNAs
regulated by glucocorticoids in astrocytes in vitro were also sta-
tistically regulated in at least one brain region by chronic cor-
ticosterone exposure in vivo (12/18 mRNAs, Figure 5). Many
mRNAs were regulated by chronic corticosterone exposure in
the same direction as the glucocorticoid regulation observed
in astrocytes in vitro and acute corticosterone exposure in vivo
(upregulated: Fkbp5, Folh1, Gjb6, Glul, Mertk, Prodh, Sgk1,
Sult1a1; downregulated: Ch25h, Hdac7, Slc1a2, Wnt7a), dis-
playing a consistent response to glucocorticoids independent of
steroid treatment duration. In contrast, several other mRNAs
in the chronic corticosterone experiment were either not reg-
ulated (Klf9, Pdk4, Txnip, Mapk4, Per1, Phlda1) or regulated
in the opposite direction (Adora2b, Egr2) when compared with
glucocorticoid regulation observed in acute corticosterone expo-
sure in vivo and astrocyte cultures in vitro. These data may
be a result of compensatory mechanisms that reverse or limit
regulation of these mRNAs under chronic glucocorticoid stimu-
lation. Unexpectedly, chronic corticosterone exposure in vivo also
regulated mRNAs that were not regulated in either acute glu-
cocorticoid exposure condition in vivo or in vitro (upregulated:
Fgfr3; downregulated: Fgfr1, Foxo1, Gap43, Gfap, Gja1, Slc1a3,
Syn2). These discrepancies may be due to indirect, compensatory
or adaptive regulation to prolonged glucocorticoid exposure. In
addition, since we assessed a single chronic corticosterone expo-
sure condition, one caveat linked to interpreting these results is
that we cannot determine if themRNAsmeasured change in other
contexts of chronic corticosterone manipulation (e.g., longer
exposures, adrenalectomy/corticosterone replacement, chronic
stress). We also do not know if these changes are transient (e.g.,
reversible with washout period), although a previous study found
long-lasting behavioral effects of chronic corticosterone expo-
sure administered via drinking water even after an abstinence
period (Gourley et al., 2008). Overall, these data provide ini-
tial evidence that astrocytes respond to chronic elevations of
glucocorticoids in vivo and potentially demonstrate secondary
regulation compared with acute glucocorticoid exposure.
A summary of the results comparing glucocorticoid regula-
tion based on glucocorticoid exposure in astrocytes in vitro, acute
corticosterone exposure in the brain in vivo, and chronic corti-
costerone exposure in the brain in vivo are shown in Figure 7.
The high concordance of in vivo regulation by corticosterone with
glucocorticoid regulation in astrocytes in vitro is important in
part because most of these mRNAs have not been reported as
glucocorticoid-sensitive in the brain in vivo. A subset of measured
mRNAs have been reported to be regulated in the brain in vivo
by glucocorticoids or stress conditions [e.g., Fkbp5 (Scharf et al.,
2011), Gfap (O’Callaghan et al., 1989), Glul (Patel et al., 1983),
Sgk1 (Sarabdjitsingh et al., 2010)], but a number of astrocyte-
enriched mRNAs demonstrate novel in vivo glucocorticoid regu-
lation in the brain (e.g., Gjb6, Prodh, Adora2b, Klf9, Pdk4, Txnip,
Folh1, Mertk, Wnt7a). Of the mRNAs with reported glucocorti-
coid regulation in the brain in vivo, the directionality matches the
previous data, giving further confidence that our data documents
authentic glucocorticoid regulation in the brain. The additional
in vivo regulation observed in these experiments may not have
been previously observed for multiple reasons; one possibility is
that the magnitude of changes are small enough that they may not
have been statistically significant if measured with techniques less
sensitive than qPCR (e.g., microarray).
In addition, these results have implications for understanding
glucocorticoid regulation in astrocytes by brain region. There is
increasing evidence of astrocyte diversity based on neuroanatom-
ical location; given the extensive differential mRNA regulation
among neurons, astrocytes may also exhibit differential mRNA
regulation by brain region. This point is also relevant given the
data comparisons to cortical astrocyte cultures in vitro (Carter
et al., 2012). Our results characterize glucocorticoid-mediated
mRNA regulation in two brain regions known to be involved
in glucocorticoid action, the prefrontal cortex and hippocam-
pus; whether these mRNAs are regulated in a similar manner in
other brain regions remains to be investigated. In response to
acute or chronic corticosterone exposure, certain mRNAs were
statistically regulated in one brain region but not the other (e.g.,
Hdac7 only in hippocampus). While there may indeed be dif-
ferential glucocorticoid mRNA regulation by brain region, such
results may be due to specific factors unique to these particu-
lar experimental conditions (e.g., exposure times, criteria used
to define differential expression). Additional experiments show-
ing consistent brain-region-dependent glucocorticoid regulation
across multiple exposure times and conditions in vivo are needed
to address this possibility.
We also noted a moderate positive correlation between the
measured mRNA changes induced by acute corticosterone expo-
sure and chronic corticosterone exposure by brain region (Acute-
Cortex vs. Chronic-Cortex: r = 0.641, Acute-Hippocampus vs.
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Chronic-Hippocampus: r = 0.720). In other words, mRNAs
regulated by glucocorticoids in one condition generally were reg-
ulated in the other condition with a similar directionality and
magnitude. Given that the mRNAs in this study were selected
based on their association with glucocorticoid regulation in
astrocytes, perhaps this pattern would be applicable to other
glucocorticoid-regulated mRNAs in astrocytes. Although we can-
not determine with these data if the observed changes in the
two conditions are occurring by similar mechanisms (e.g., direct
regulation by glucocorticoid receptor), these correlations suggest
that robust glucocorticoid sensitivity may be able to induce reg-
ulation of select mRNAs in the brain independent of exposure
duration.
Although we have substantiated the notion of glucocorticoid
regulation in vivo of mRNAs regulated by glucocorticoids in
astrocytes in vitro via qPCR, we cannot localize mRNA regula-
tion to specific cell types in a multicellular brain tissue sample
using this technique. In order to examine the neuroanatomical
nature of these glucocorticoid-regulated mRNAs in vivo, we per-
formed in situ hybridization studies on brain tissue from the
chronic corticosterone exposure experiments (e.g., mice chron-
ically exposed to corticosterone solution or vehicle solution).
Using semi-quantitative densitometry, we were able to assess the
glucocorticoid regulation of a number ofmRNAs in the prefrontal
cortex and/or hippocampus by ISH (Figure 6). Although only a
subset of differential expression as measured by qPCR were vali-
dated by ISH, the ISH data was directionally consistent with the
qPCR data in almost all cases; the discrepancy of statistical signif-
icance may be in part due to a more robust sensitivity of qPCR
measurements.
The hippocampus has a well-known cytoarchitecture that can
readily associate cell types with specific locations in this brain
region. Within the hippocampus, there are well-known layers
such as the pyramidal cell layer in the hippocampal subfields (e.g.,
dentate gyrus, CA1, CA2, CA3), which is characterized by a higher
density of neurons compared with other regions. In contrast, the
molecular layer contains a relatively lower neuron density. We
thus examined the neuroantomical expression patterns of these
6 mRNAs in an effort to associate the observed mRNA regulation
with the location of specific cell types. Similarly general expres-
sion patterns of these mRNAs were observed by ISH in sections
from both vehicle-treated animals and corticosterone-treated ani-
mals, suggesting that the observed changes are likely occurring in
cells that express these mRNAs under basal conditions. Among
mRNAs measured, we detected ISH signal for Fkbp5 predomi-
nately in the pyramidal cell layer throughout multiple hippocam-
pal subfields (Figure 6A). Following chronic glucocorticoids, the
hybridization signal appears to rise across the pyramidal cell layer
of the hippocampal subfields without any noticeable increase in
signal in the molecular layer. While additional high resolution
images will be necessary to fully determine in which cell types
Fkbp5 is being regulated, this expression pattern suggests the
mRNA regulation occurs in pyramidal neuronal cell populations.
In contrast, mRNAs regulated by chronic corticosterone but not
expressed in pyramidal cell regions may be regulated in other cell
types (e.g., astrocytes). Strikingly, all of the other corticosterone-
regulated mRNAs analyzed by ISH in this study demonstrate very
low or undetectable levels of expression in pyramidal neuron
subfields (Gfap, Glul, Gja1, Gjb6). The gene expression patterns
of these mRNAs appear much more homogeneous across the
hippocampus, an anatomical distribution that is largely consis-
tent with the reported distribution of astrocytes in this tissue
(Ogata and Kosaka, 2002; de Vivo et al., 2010). Importantly, these
mRNAs also show similar expression patterns as that of Aldh1l1,
a mRNA previously shown to be substantially enriched in astro-
cytes and described as a pan-astrocytic marker (Cahoy et al.,
2008). While further studies will be required to definitively iden-
tify the cell type of this differential glucocorticoid-sensitive gene
expression, given the similar general expression patterns of these
mRNAs between corticosterone-treated and vehicle treated ani-
mals along with the highly similar anatomical distribution of
Gja1, Gbj6, and Glu1 the pan-astrocytic marker Aldh1l1, these
results are consistent with the hypothesis that these mRNAs are
regulated by chronic glucocorticoid exposure in astrocytes in vivo.
We also note a differential regulation of astrocyte cell mark-
ers by corticosterone treatment in vivo that may be important
for future studies of glucocorticoid signaling involving astro-
cytes. Gfap, a cytoskeletal filament and a marker historically
associated with astrocytes in the brain, yields a different expres-
sion pattern compared with the pan-astrocytic marker Aldh1l1
and the other astrocyte-enriched mRNAs in the hippocampus
(Figure 6A). Gfap mRNA is detected at relatively lower levels
throughout the hippocampus but at relatively higher levels at
the boundary of the structure; this boundary expression is con-
sistent with previously reported Gfap expression in ependymal
cells (i.e., pial distribution) (Liu et al., 2006). Following chronic
glucocorticoid-treatment, Gfap mRNA levels decrease across all
areas (ependymal cells and non-pyramidal cell areas of the hip-
pocampus), consistent with our qPCR data and previous reports
(O’Callaghan et al., 1989). Recent studies on major depression
have used Gfap in human postmortem experiments and animal
models of depression to measure astrocyte cell number; multi-
ple reports have reported decreased astrocyte cell density in these
conditions based on Gfap protein measurements (e.g., Rajkowska
et al., 1999; Miguel-Hidalgo et al., 2000). However, this inter-
pretation may be confounded by glucocorticoid-induced down-
regulation of Gfap mRNA and corresponding protein in these
conditions associated with hypercortisolemia. If astrocyte cell
numbers are changing, then all astrocyte markers would also be
expected to change in parallel. We havemeasured Aldh1l1, a more
recently identified pan-astrocyte marker, and found that Aldh1l1
is not downregulated by glucocorticoids under anymeasured con-
dition (in contrast, our ISH data suggest possible upregulation
by chronic corticosterone exposure). These findings suggest that
astrocyte numbers may not be decreasing but that the astrocyte
cytoskeleton is dynamically regulated in conditions of hypercorti-
solemia. Additional cell counting studies using Gfap and Aldh1l1
are needed to clarify this issue. In general, future studies in astro-
cytes would benefit from using multiple cell markers or a marker
known not to be affected by any component of the manipulation
or disease of interest.
What are the functional consequences of glucocorticoid reg-
ulation in astrocytes in vivo? We can project functional alter-
ations based on the known roles of the mRNAs measured. Two
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potential functional alterations involve gap junction coupling
and glutamate signaling. Astrocytes express two main gap junc-
tion proteins, connexin-30 (Gjb6) and connexin-43 (Gja1). Gjb6
was strongly upregulated by both acute and chronic corticos-
terone exposure in vivo, while Gja1 was downregulated by chronic
corticosterone exposure. Changes in these gap junctions would
likely alter the permeability within astrocytes and between astro-
cytes and other cells [e.g., oligodendrocytes (Orthmann-Murphy
et al., 2007)], a significant alteration given the important role of
gap junctions in intercellular communication among astrocytes.
Astrocytes also play an important role in glutamate signaling,
both in terms of glutamate synthesis and glutamate transport.
While glucocorticoids have been known to increase glutamine
synthetase (Glul) expression, we observed that chronic gluco-
corticoid exposure decreased the expression of both astrocytic
glutamate transporters, GLT-1 (Slc1a2) and GLAST (Slc1a3).
Decreases in astrocyte glutamate uptake have been reported in
chronic stress conditions (Almeida et al., 2010; de Vasconcellos-
Bittencourt et al., 2011); our results suggest that impairment of
glutamate transport could be mediated by chronic glucocorticoid
exposure, a potential mechanism for the changes seen in chronic
stress.
These data also have interesting parallels to clinical findings in
postmortem studies of major depression, a condition associated
with elevations of glucocorticoids. Multiple mRNAs regulated by
chronic corticosterone exposure in this study are reported to be
changed in the same direction in human depression (e.g., down-
regulation of Gja1, Slc1a2, and Slc1a3) (Bernard et al., 2010).
While the data presented in these studies cannot be directly
linked to depression biology, they do provide a potential mech-
anism (glucocorticoid regulation) by which these genes may be
altered. Alterations of astrocyte-enriched fibroblast growth factor
(FGF) receptors observed here (upregulation of Fgfr3, downreg-
ulation of Fgfr1) may also be relevant to depression biology given
the findings of altered expression of FGF receptors and ligands
in depression (Evans et al., 2004). We would be interested in
determining if these same mRNAs are regulated in other animal
models demonstrating chronically elevated corticosterone lev-
els, such as animal models of depression. Given the associations
of increased depressive-like behavior and astrocyte dysfunction
(Banasr and Duman, 2008), perhaps these mRNAs are relevant
to the underlying mechanisms of these observations. A caveat of
such extrapolations is that we have documented glucocorticoid-
mediated mRNA changes but not changes in corresponding pro-
teins; further studies are needed to measure correlations between
glucocorticoid-mediated changes in mRNA expression and any
changes in corresponding protein levels.
In summary, our data demonstrate that select mRNAs regu-
lated by glucocorticoids in astrocytes in vitro are also regulated
by acute and/or chronic corticosterone exposure in vivo. A num-
ber of these mRNAs have been reported as astrocyte-enriched
(Cahoy et al., 2008), and ISH data of anatomical expression pat-
terns within the hippocampus suggest that certainmRNA changes
occur within regions containing astrocytes. Together, these data
suggest that the observed glucocorticoid-mediated mRNA regu-
lation may be occurring in astrocytes. These data add physiolog-
ical significance to parallel gene expression findings in astrocyte
cell culture and suggest that additional findings of glucocorti-
coid regulation in astrocyte cultures in vitro may extend to the
brain in vivo. Based on these results, we posit that differential
responses to glucocorticoids by cell type is an important factor for
fully understanding glucocorticoid-mediated mechanisms in the
brain. The functional contribution of glucocorticoid regulation in
astrocytes to stress signaling remains to be investigated and may
be integral to both the classical stress response and pathological
conditions associated with elevations in glucocorticoid levels in
the brain.
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